Turn Therapeutics (NASDAQ:TTRX) Announces Quarterly Earnings Results

Turn Therapeutics (NASDAQ:TTRX) announced its quarterly earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, Zacks reports.

Turn Therapeutics Stock Performance

Shares of Turn Therapeutics stock traded down $0.06 during trading on Wednesday, hitting $3.14. 13,785 shares of the stock traded hands, compared to its average volume of 30,404. The company has a market capitalization of $92.58 million and a PE ratio of -44.91. Turn Therapeutics has a 52 week low of $2.57 and a 52 week high of $26.50. The business has a fifty day simple moving average of $3.71.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Weiss Ratings assumed coverage on Turn Therapeutics in a research report on Monday, January 5th. They issued a “sell (e-)” rating on the stock. D. Boral Capital restated a “buy” rating and set a $8.00 target price on shares of Turn Therapeutics in a research report on Tuesday, March 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TTRX. Hodges Capital Management Inc. purchased a new position in shares of Turn Therapeutics during the fourth quarter worth approximately $39,000. LPL Financial LLC bought a new position in shares of Turn Therapeutics during the 4th quarter valued at $51,000. Jane Street Group LLC bought a new position in shares of Turn Therapeutics during the 4th quarter valued at $68,000. Geode Capital Management LLC purchased a new position in Turn Therapeutics in the 4th quarter worth $68,000. Finally, HighTower Advisors LLC bought a new stake in Turn Therapeutics in the fourth quarter worth $78,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.